Adjuvant therapy in stage IIIA melanoma: Cost vs Benefit of gene profiling

Source: MedicalResearch.com, September 2020

MedicalResearch.com: What is the background for this study?

Response: Indications for adjuvant therapy for resected, high-risk melanoma is a controversial and rapidly-evolving topic in melanoma treatment.

Immunotherapy treatments targeting PD-1 have significantly improved survival in advanced-stage disease, but the magnitude of survival benefit in stage III disease–particularly stage IIIA–remains unclear.

Recently, 31-GEP (a gene expression profiling assay) has been studied as a risk-stratifying tool to identify patients who are at higher risk for systemic recurrence. Ideally such a tool could identify patients most likely to benefit from immunotherapy treatment in the adjuvant setting (when all visible disease has been removed).

READ THE ORIGINAL FULL ARTICLE